Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors
June 10 2021 - 8:00AM
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage
company developing transformative therapies for the treatment of
cancer and rare diseases with significant unmet needs, today
announced the appointment of Jane Huang, M.D. to its Board of
Directors. Dr. Huang, an experienced biotech executive and proven
leader throughout the development lifecycle of multiple oncology
therapeutics globally, currently serves as Chief Medical Officer,
Hematology at BeiGene, Ltd.
“It is a great privilege to welcome Dr. Huang to
our Board of Directors,” said Jesse Shefferman,
Chief Executive Officer of Protara Therapeutics. “As a proven
industry leader with extensive oncology drug development
experience, we believe Dr. Huang’s insights will be invaluable as
we continue to advance TARA-002, our lead product candidate, for
the treatment of both non-muscle invasive bladder cancer and
lymphatic malformations.”
“It is a pleasure to join the Protara Board of
Directors at such an exciting time in the Company’s evolution,”
said Dr. Huang. “I look forward to working with the talented
leadership team as they continue to execute on their mission of
bringing transformative therapies to patients with cancer and rare
diseases.”
At BeiGene, Dr. Huang oversees hematology drug
development, and played a key role in the first approval of
tislelizumab, BeiGene’s PD-1 inhibitor, and zanubrutinib, BeiGene’s
BTK inhibitor. Prior to joining BeiGene, Dr. Huang was the Vice
President and Head of Development at Acerta Pharma, where she
oversaw global clinical development of the BTK inhibitor
acalabrutinib. Previously, she served as Group Medical Director at
Genentech where she played a leading role in drug development
programs for several molecules at all stages of development,
including venetoclax and obinutuzumab. Dr. Huang also currently
serves as a Clinical Assistant Professor (adjunct), Thoracic
Oncology, at Stanford University.
Dr. Huang received her Bachelor of Science
degree in Biological Sciences from Stanford University and her M.D.
from University of Washington School of Medicine. She is board
certified in Hematology, Oncology and Internal Medicine, and she
completed her residency in Internal Medicine and fellowships in
Hematology and Oncology at Stanford University.
About Protara Therapeutics, Inc.
Protara is committed to identifying and
advancing transformative therapies for people with cancer and rare
diseases with limited treatment options. Protara’s portfolio
includes its lead program, TARA-002, an investigational cell-based
therapy being developed for the treatment of non-muscle invasive
bladder cancer and lymphatic malformations, and IV Choline
Chloride, an investigational phospholipid substrate replacement
therapy for the treatment of intestinal failure-associated liver
disease. For more information, visit www.protaratx.com.
Forward-Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are "forward
looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Protara may, in some cases, use
terms such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “designed,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words or expressions referencing future events, conditions or
circumstances that convey uncertainty of future events or outcomes
to identify these forward-looking statements. Such forward-looking
statements include but are not limited to, statements regarding
Protara’s intentions, beliefs, projections, outlook, analyses or
current expectations concerning, among other things: Protara’s
business strategy, Protara’s development plans for its product
candidates and the contribution of Dr. Huang’s experience and past
accomplishments in helping us achieve our strategic objectives,
including the advancement of our programs. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Factors that contribute to the uncertain nature of the
forward-looking statements include: risks that Protara’s sales,
revenue, expense and other financial guidance may not be as
expected, as well as risks and uncertainties associated with:
Protara’s development programs, including the initiation and
completion of non-clinical studies and clinical trials and the
timing of required filings with the FDA and other regulatory
agencies; the impact of the COVID-19 pandemic on Protara’s business
and the global economy; general market conditions; changes in the
competitive landscape; changes in Protara’s strategic and
commercial plans; Protara’s ability to obtain sufficient financing
to fund its strategic plans and commercialization efforts; having
to use cash in ways or on timing other than expected; the impact of
market volatility on cash reserves; the loss of key members of
management; and the risks and uncertainties associated with
Protara’s business and financial condition in general, including
the risks and uncertainties described more fully under the caption
"Risk Factors" and elsewhere in Protara's filings and reports with
the United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made and are based on
management's assumptions and estimates as of such date. Protara
undertakes no obligation to update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise, except as required by
law.
Company Contact:
Justine O'MalleyProtara
TherapeuticsJustine.OMalley@protaratx.com646-817-2836
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jul 2023 to Jul 2024